Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cocrystal Pharma, Inc. on November 13, 2018. The report discloses a presentation delivered by Dr. Sam Lee, President of the Company, at the 6th ISRV AVG Conference in Washington, DC. The presentation focused on the preclinical characterization of CC-42344, a broad-spectrum influenza A PB2 inhibitor.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a scientific presentation and does not contain financial statements or operational financial data.
Material Changes
No material financial changes versus a prior comparable period are reported in this filing. The document serves solely to disclose the conference presentation regarding the Company's drug candidate.
Guidance, Outlook, and Risks
The filing includes a presentation on preclinical data for CC-42344. The Company explicitly states that the information in this report, including exhibits, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to liabilities under such section. Furthermore, the information shall not be deemed incorporated by reference into any other filings under the Securities Act of 1933 or the Exchange Act.
Key Facts for Investor Verification
- The Company presented preclinical data on CC-42344, an influenza A PB2 inhibitor, on November 13, 2018.
- The presentation is included as Exhibit 99.1 to this filing.
- The disclosure is made under Item 7.01 (Regulation FD Disclosure) and does not constitute a formal filing of financial data.
- Investors should verify the clinical status and regulatory pathway of CC-42344 through subsequent filings or the referenced presentation.